Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

This study tests combining a targeted antibody (tafasitamab, which attacks a protein on leukemia cells) with standard chemotherapy for adults who are newly diagnosed with a specific type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that lacks the Philadelphia chromosome. **You may be eligible if...** - You are 18 or older with a new diagnosis of CD19-positive B-cell ALL - You are not considered a good candidate for the most intensive "pediatric-inspired" chemotherapy regimens (perhaps due to older age or other health factors) - Your liver, kidney, and blood counts are adequate - Your cancer is confirmed to be Philadelphia chromosome-negative **You may NOT be eligible if...** - Your ALL has the Philadelphia chromosome mutation - You have received prior treatment for this leukemia - Your liver or kidney function is severely impaired - You have active serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.